Ultragenyx Pharmaceutical Inc.
RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypopā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$33.08
Price+0.55%
$0.18
1Y
Price
Market Cap
$3.186b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-54.9%
EBITDA Margin-69.0%
Net Profit Margin-57.5%
Free Cash Flow MarginRevenue
$610.159m
+8.9%
1y CAGR+19.2%
3y CAGR+15.2%
5y CAGREarnings
-$532.932m
+6.4%
1y CAGR+8.9%
3y CAGR-7.3%
5y CAGREPS
-$5.53
+12.1%
1y CAGR+18.1%
3y CAGR+0.8%
5y CAGRBook Value
$158.286m
$1.306b
Assets$1.148b
Liabilities$882.908m
DebtDebt to Assets
67.6%
-2x
Debt to EBITDAFree Cash Flow
-$427.301m
-1.3%
1y CAGR+6.3%
3y CAGR-2.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company